Benitec Biopharma (BNTC) vs Greenwich LifeSciences (GLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Benitec Biopharma (BNTC) over the past year, gaining 136.2% versus a loss of 40.3%. Over five years, GLSI leads with a -41.8% price change compared with -85.7% for BNTC. Benitec Biopharma is the larger company by market cap ($285.9 million vs $282.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | GLSI |
|---|---|---|
| Share price | $7.92 | $19.25 |
| Market cap | $285.88M | $282.56M |
| 1-day change | -2.76% | -2.73% |
| YTD return | -41.24% | -8.38% |
| 1-year return | -40.31% | +136.20% |
| 5-year return | -85.67% | -41.84% |
| EPS (TTM) | $-1.02 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-45.55M | $-19.36M |
| 52-week high | $14.39 | $34.10 |
| 52-week low | $7.72 | $7.78 |
| Distance from 52-week high | -45.00% | -43.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +200.06% | +198.70% |
| Average volume | 174.01K | 160.76K |
| Shares outstanding | 36.12M | 14.68M |
| Employees | 24 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed BNTC by 176.5 percentage points over the past year.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
BNTC vs GLSI FAQ
Which is bigger, Benitec Biopharma or Greenwich LifeSciences?
Benitec Biopharma (BNTC) is larger, with a market capitalization of $285.88M compared with $282.56M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, BNTC or GLSI?
GLSI returned +136.20% over the past 12 months, compared with -40.31% for BNTC (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Greenwich LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.